Leniolisib treatment for people with activated PI3K delta syndrome (APDS): a plain language summary of the phase 3 study
Rattachement africain : is, us, cz, ru, it, de, ie, gb, nl. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Plain language summaryWhat is this summary about? This is a plain language summary of an article originally published in Blood. Leniolisib is a drug developed to treat activated PI3K delta syndrome (APDS). APDS is a rare disease in which the immune system does not work correctly. People with APDS have a wide range of symptoms including infections, certain organs associated with the immune system becoming larger, and worse quality of life. This summary reports the results from a clinical study that aimed to understand if leniolisib is effective at treating people with APDS.What were the results? The study showed that leniolisib improved the amounts of immune cells and antibodies (proteins that help the immune system to function). Leniolisib also reduced the size of participants' enlarged organs, and lowered the activity of the protein that causes APDS. There were no major safety concerns for participants who took leniolisib.What do the results mean? These results indicate that leniolisib helps the immune system to work in a way that is closer to those without APDS. By helping the immune system, leniolisib may be able to improve the lives of people with APDS by making them feel better. Leniolisib may also prevent difficulties in completing activities in the daily lives of people with APDS.Clinical Trial Registration: NCT02435173 (ClinicalTrials.gov)
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Leniolisib treatment for people with activated PI3K delta syndrome (APDS): a plain language summary of the phase 3 study
- Date Crossref
- 21/08/2024
- Éditeur
- Informa UK Limited
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Directorate of Health pays non établi dans la noticeOrganisme public
-
Frederick National Laboratory for Cancer Research pays non établi dans la noticeStructure de recherche
-
National Institutes of Health pays non établi dans la noticeOrganisme public
-
National Institute of Allergy and Infectious Diseases pays non établi dans la noticeStructure de recherche
-
Charles University pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital in Motol pays non établi dans la noticeÉtablissement de santé
-
Brescia University pays non établi dans la noticeUniversité ou école supérieure
-
Scientific Research Institute of Experimental and Clinical Medicine pays non établi dans la noticeStructure de recherche
-
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia pays non établi dans la noticeÉtablissement de santé
-
Institute of Clinical and Experimental Medicine pays non établi dans la noticeÉtablissement de santé
-
University of Brescia Pediatrics Clinic pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital Carl Gustav Carus pays non établi dans la noticeÉtablissement de santé
Directorate of Health, Frederick National Laboratory for Cancer Research et National Institutes of Health, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.